RecruitingPHASE1, PHASE2NCT04422912
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Studying Pemphigus vulgaris
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cabaletta Bio
- Principal Investigator
- Cabaletta BioCabaletta Bio
- Intervention
- DSG3-CAART(biological)
- Enrollment
- 40 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2029
Study locations (13)
- Stanford University, Dept. of Dermatology, Redwood City, California, United States
- UC Davis, Dept. of Dermatology, Sacramento, California, United States
- Yale University, New Haven, Connecticut, United States
- Northwestern University, Chicago, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Mount Sinai - Icahn School of Medicine, New York, New York, United States
- Columbia University, New York, New York, United States
- University of North Carolina, Department of Dermatology, Chapel Hill, North Carolina, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- UT Southwestern Medical Center, Dept. of Dermatology, Dallas, Texas, United States
- MD Anderson Texas Medical Center, Houston, Texas, United States
- University of Washington, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04422912 on ClinicalTrials.govOther trials for Pemphigus vulgaris
Additional recruiting or active studies for the same condition.